On Dec. 18, 2024, the U.S. Food and Drug Administration (FDA) approved Ensacove (ensartinib) for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an ALK mutation and have not previously received an ALK-targeted therapy. [...]
By Shelly Engfer-Triebenbach I was just finishing up my 18th year of teaching music when I noticed myself getting short of breath doing easy things. I went to see my primary care doctor who gave me antibiotics and [...]
Sydney Barned, MD, was 33 years old and in her medical residency when she was diagnosed with stage 4 ALK-positive lung cancer. A year prior to diagnosis, she woke up with severe shortness of breath and decided she needed [...]
On May 22, 2020, the Food and Drug Administration (FDA) approved Alunbrig (brigatinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in ALK. The FDA based their approval on the results [...]
SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ -- ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung [...]